Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 20/20 | 0.74 |
| ▸ | ABHD6 | Q9BV23 | 5/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | PLA2G7 | Q13093 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20137407 | 1.00 | MGLL (0.74) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL20178047 | 1.00 | MGLL (0.74) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL20150051 | 0.90 | MGLL (0.64) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL20155798 | 0.89 | MGLL (0.67) | MGLLABHD6PLA2G7 | |
| SCHEMBL20155797 | 0.89 | MGLL (0.67) | MGLLABHD6PLA2G7 | |
| SCHEMBL24308869 | 0.89 | MGLL (0.66) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL20137403 | 0.88 | MGLL (0.58) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL20155493 | 0.88 | MGLL (0.58) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL20182425 | 0.85 | MGLL (1.00) | MGLL | |
| SCHEMBL20182660 | 0.85 | MGLL (1.00) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| EP-3541822-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2022-01-19 | — | — | EP | disclosed |
| WO-2020154683-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-9981930-B1 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| WO-2018093946-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180134675-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | MGLL, LIPA, PNLIP | MGLL 1/4885ABHD6 49/4885CYP2D6 4514/4885 |
| US-20180134675-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MGLL 3/4885ABHD6 563/4885CYP2D6 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.